DexCom Inc. (DXCM)
NASDAQ: DXCMHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
DXCM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $31.81B
- P/E (TTM)
- 33.45
- Forward P/E
- 26.96
- EPS (TTM)
- $2.52
- Dividend yield
- None
- 52-week range
- 54.11 – 92.59
- Day range
- 83.80 – 85.70
- Volume / Avg
- 2.86M / 4.48M
- Beta
- —
- Shares outstanding
- 377.36M
- Next earnings
- Oct 29, 2026
52-week range
DXCM stock today
Shares of DexCom (DXCM) finished higher on Oct 7 at $84.30, a gain of 1.09% or $0.91 per share, versus the S&P 500's 0.22% decline. At this level, DXCM sits in the middle of its 52-week range of $54.11 to $92.59: 9.0% below the high, set on Aug 24, 2026 and 55.8% above the low. DXCM is up 27.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 27.7%.
At 33.5x trailing earnings, DexCom trades below the peer-group median of 44.4x. Its forward P/E of 27.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. DexCom's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About DexCom
Company profileDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Jacob Steven Leach
- Headquarters
- San Diego, CA
- Employees
- 11,000
- IPO year
- 2005
- Website
- dexcom.com
Financial highlights
Full financialsIn fiscal 2025, DexCom generated $4.66 billion in revenue, up 15.6% from fiscal 2024, its 16th consecutive year of revenue growth. Net income was $836.3 million (+45.1% year over year), for a net margin of 17.9% versus a median of 14.3% in the prior 5 years. Gross margin was 60.1% (down from 60.5%) and operating margin 19.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B | $2.45B |
| Growth | +15.60% | +11.34% | +24.49% | +18.84% | +27.08% |
| Net income | $836.30M | $576.20M | $541.50M | $341.20M | $216.90M |
| EPS (diluted) | $2.09 | $1.42 | $1.30 | $0.82 | $0.53 |
Analyst forecast
ForecastConsensus (29 analysts)
strong_buy
Avg. price target
$96.23+14.15%
- Strong buy 4
- Buy 22
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $0.66
- Last reported (Q2 2026)
- Jul 30, 2026
- EPS actual vs est.
- $0.64 vs —
DXCM news
All DXCM newsDexCom peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RMDResMed Inc. | 225.98 | +2.40% | $31.78B | vs DXCM |
| WSTWest Pharmaceutical Services Inc. | 366.48 | -1.65% | $25.79B | vs DXCM |
| MDLNMedline Inc. Class A | 35.45 | -0.28% | $47.70B | vs DXCM |
| SOLVSolventum Corporation | 85.88 | -1.33% | $14.62B | vs DXCM |
| BDXBecton Dickinson and Company | 180.16 | -0.08% | $49.07B | vs DXCM |
| PENPenumbra Inc. | 316.35 | -0.22% | $12.46B | vs DXCM |
| BAXBaxter International Inc. | 23.97 | -1.60% | $12.39B | vs DXCM |
| GKOSGlaukos Corporation | 172.18 | +6.55% | $10.16B | vs DXCM |
Indexes, lists and sector
Index membership
DexCom stock FAQ
What is DexCom's stock price today?
DXCM last traded at $84.30 as of Oct 7, 4:00 PM EDT, up 1.09% on the day. Prices are delayed at least 15 minutes.
Does DexCom pay a dividend?
No. DexCom does not currently pay a regular cash dividend.
When is DexCom's next earnings date?
DexCom is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $0.66.
What is DXCM's P/E ratio?
DXCM trades at a trailing P/E ratio of 33.45 and a forward P/E of 26.96, compared with a median of 44.4 for its closest peers.
Is DexCom in the S&P 500?
Yes. DexCom (DXCM) is a constituent of the S&P 500 index.
Who is DexCom's CEO?
Mr. Jacob Steven Leach is the chief executive officer of DexCom Inc., which has about 11,000 employees.
Has DXCM ever split its stock?
Yes. The most recent DXCM stock split was a 4-for-1 split on Jun 13, 2022.